Loading organizations...
§ Private Profile · Palo Alto, CA, USA
clinical-stage biotechnology company developing inhaled therapies, focused on chronic obstructive pulmonary disease (COPD).
AirNexis Therapeutics is a clinical-stage biotechnology company developing inhaled therapies for chronic obstructive pulmonary disease, based in Palo Alto, California, United States. The enterprise focuses on advancing its investigational lead candidate, AN01, a dual PDE3/4 inhibitor designed to expand airways and reduce inflammatory factors through multiple dosage forms. The company in-licensed exclusive development and commercialization rights for AN01 outside of China from Haisco Pharmaceutical Group, which recently launched three Phase 2 trials for the investigational inhaler. Led by Chief Executive Officer Maria Fardis and Chairman James Li, the firm secured a $200 million Series A financing round to support its clinical pipeline. Additional equity backing was provided by prominent healthcare investors including OrbiMed, SR One, Longitude Capital, Enavate Sciences, and Life Sciences at Goldman Sachs Alternatives. AirNexis Therapeutics was founded in 2026 by Frazier Life Sciences.
AirNexis Therapeutics has raised $200.0M across 1 funding round.
AirNexis Therapeutics has raised $200.0M in total across 1 funding round.
AirNexis Therapeutics has raised $200.0M across 1 funding round. Most recently, it raised $200.0M Series A in January 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 12, 2026 | $200M Series A | Anna Chen | Enavate Sciences, Longitude Capital, Evan Caplan, Jill Carroll | Announced |
AirNexis Therapeutics has raised $200.0M in total across 1 funding round.
AirNexis Therapeutics's investors include Anna Chen, Enavate Sciences, Longitude Capital, Evan Caplan, Jill Carroll.